Andrea Bisso: Exploring the T Cell Engagers in Autoimmune Diseases
Andrea Bisso, Senior Director of Scientific Alliances – Head of Europe, shared a post on Linkedin about a recent article by Ricardo Grieshaber-Bouyer, published in Nature Reviews Immunology, adding:
“T cell engagers in autoimmune diseases
A paper a day keeps brain decay away
Thursday 2 July 2026
Despite advances in immunology, achieving durable, drug-free remission in refractory autoimmune diseases remains elusive due to incomplete B cell depletion
in tissue sanctuaries.
This perspective highlights how T cell engagers – off-the-shelf, bispecific antibodies – harness potent T cell-dependent cellular cytotoxicity to achieve deep B cell eradication and an unprecedented immune reset.
Take-home messages
- TCEs redirect endogenous T cells to eliminate autoreactive B cells through T cell-dependent cellular cytotoxicity, combining CAR T-like potency with the convenience of an off-the-shelf biologic.
- More than 30 TCEs targeting CD19, CD20 and B cell maturation antigen (BCMA) are already in clinical development across systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, myasthenia gravis and other autoimmune diseases.
- Next-generation engineering focuses on improving the therapeutic index through optimized CD3 affinity, multispecific designs, conditional activation and subcutaneous administration.
Why this matters
- TCEs could shift treatment from long-term immune suppression to immune reset, while remaining repeatable, scalable and immediately available.
A Key challenges
- Can efficacy be maintained while further reducing cytokine release syndrome?
- Which B-cell target delivers the deepest and most durable remission?
- Which patients require complete immune reset versus controlled immune modulation?”
Title: T cell engagers in autoimmune diseases
Authors: Ricardo Grieshaber-Bouyer, Lei Wu, Georg Schett, Patrick A. Baeuerle
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 13, 2026, 14:40Cheryl Loetscher: This Day in Drug Discovery – Wakix and H3 Receptor Inverse Agonism in Narcolepsy
-
Oct 13, 2026, 14:30Thirunavukkarasu Angappan: FVIII vs. FIX Expressive Durability – Key Lessons from GENEr8-1 and HOPE-B Long-Term Data
-
Oct 13, 2026, 14:25Alyaa Al-Mughairy: Highlights from the 8th Omani Society of Hematology Congress
-
Oct 13, 2026, 14:21Britta Diebel: Reflections on an Unforgettable International Plasma Awareness Week
-
Oct 13, 2026, 14:14ESPHO at MAX Cancer Congress 2026: Advancing Ethiopian Pediatric Oncology on the Global Stage
-
Oct 13, 2026, 14:05Antonella Cordoba: WFH Representatives Visit the Hemophilia Foundation of Argentina
-
Oct 13, 2026, 13:56John Strouse: Screening for FNAIT – What HDN Teaches Us About Preventing Newborn Intracranial Hemorrhage
-
Oct 13, 2026, 12:29Mariam Al Mansoori: 5th International Hemophilia Conference
-
Oct 13, 2026, 12:13Hemophilia Outreach of Wisconsin Attends VWD Connect Conference